Arkgen Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.10 M
as on 09-12-2024
- Paid Up Capital ₹ 5.10 M
as on 09-12-2024
- Company Age 10 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.80 Cr
as on 09-12-2024
- Revenue 36.01%
(FY 2022)
- Profit 151.88%
(FY 2022)
- Ebitda 311.02%
(FY 2022)
- Net Worth 65.36%
(FY 2022)
- Total Assets 49.45%
(FY 2022)
About Arkgen Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.10 M and a paid-up capital of Rs 5.10 M.
The company currently has active open charges totaling ₹2.80 Cr.
Padiyath Akbarali, Hathika Akbarali, and Amal Padiyath serve as directors at the Company.
- CIN/LLPIN
U74900KA2014PTC075574
- Company No.
075574
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Jul 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Arkgen Pharma Private Limited offer?
Arkgen Pharma Private Limited offers a wide range of products and services, including Brain & Nervous System Drugs, Psychotherapeutic Agents, Pharma Ingredients & Raw Materials, Nervous System and Antipsychotic API, Antibacterial Drugs, Linezolid Oral Suspension, Antidepressant & Anti Anxiety Medicines, Pregabalin Capsules, Anti Cancer Medicines, Geftinat Tablet.
Who are the key members and board of directors at Arkgen Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Padiyath Akbarali  | Director | 30-Jul-2014 | Current |
| Hathika Akbarali | Director | 19-May-2016 | Current |
| Amal Padiyath | Director | 26-Aug-2021 | Current |
Financial Performance of Arkgen Pharma.
Arkgen Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 36.01% increase. The company also saw a substantial improvement in profitability, with a 151.88% increase in profit. The company's net worth Soared by an impressive increase of 65.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Arkgen Pharma?
In 2021, Arkgen Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Arkgen Enterprises Private LimitedActive 19 years 1 monthPadiyath Akbarali and Hathika Akbarali are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 21 Oct 2019 | ₹1.80 Cr | Open |
State Bank Of India Creation Date: 15 Mar 2016 | ₹1.00 Cr | Open |
How Many Employees Work at Arkgen Pharma?
Arkgen Pharma has a workforce of 17 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Arkgen Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Arkgen Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
